Professionals
Published by Andrea Stearns
Last Updated On December 1, 2025

Botox and Fillers​ in Combination — Explaining the Synergy

Dec 1, 2025

Facial aging results from gradual changes in the skin, underlying fat, muscles, ligaments, and bone. Addressing these changes requires a multifaceted approach that targets all relevant tissue layers. No single intervention currently can treat all the signs of aging. 

Combination therapy consisting of Botox and fillers is increasingly becoming standard practice. The goal of combination treatment is to relax dynamic lines, restore volume, improve tissue quality, and achieve harmonious facial rejuvenation. 

This article summarizes the current consensus guidelines that explain the synergy between botulinum toxin type A and hyaluronic acid. 

Key Takeaways: 

• Combination Botox and fillers targets multiple drivers of aging simultaneously. Neuromodulators reduce dynamic muscle activity, and hyaluronic acid fillers restore volume.
• The key areas for combination therapy are persistent glabellar lines, horizontal forehead rhytides, tear troughs, zygomatic and perioral contour changes, and jawline/neck deflation.
• Patients generally report higher satisfaction with combination therapy than with Botox or dermal fillers alone.
• Combination therapy carries a higher risk of adverse events compared with single modalities.
• Although it is possible to administer both Botox and fillers in one go, a staged approach is recommended. 

Areas of Combination Botox and Filler Treatments

To date, no single modality can reliably address all age-related changes across the upper, mid, and lower face. Therefore, multimodal strategies are the standard of care in aesthetic practice.

Contemporary consensus guidelines emphasize combining hyaluronic acid fillers and neuromodulators for the following areas:¹

• Persistent glabellar lines with deeply etched, static rhytides that remain even at rest
• Height adjustment of the brow complex, i.e., frontalis, brow fat pads, and the retaining ligaments along the superior orbital rim
• Horizontal forehead lines that appear to compensate for upper-lid ptosis
• Nasojugal folds, commonly called the tear trough
• Resetting the contours in the zygomatic and perioral regions
• Blunting of the jawline, banding, and loss of neck definition

Why Combine Botox and Fillers? The Scientific Rationale

Combining botulinum toxin type A and hyaluronic acid fillers addresses different primary drivers of facial aging.

Synergistic Mechanism of Action

At the tissue level, botulinum toxin type A (BoNT‑A) reduces dynamic muscle contraction by temporarily inhibiting acetylcholine release from presynaptic terminals. Neuromodulation decreases the mechanical stress that repetitive muscle movement imposes on overlying skin.

In contrast, hyaluronic acid (HA) fillers restore volume through their viscoelastic and hydrophilic properties. They replace the lost soft tissue projection in areas of atrophy.

When used together, the two approaches complement each other. The results of combination therapy are qualitatively better than treatment alone.

Better Patient-Reported Satisfaction

Patients tend to report greater satisfaction with combination treatment than with single-modality therapy. That’s in part because it permits the use of small-gauge needles and can cut the total number of injection passes by half or more.²

In a multicenter clinical trial, 96.5% of patients were at least “satisfied” three weeks after combined BoNT‑A and HA injections, and 92.9% maintained satisfaction at six months.³

Another randomized study in the lower face showed that the combination of onabotulinumtoxinA and a 24 mg/mL cohesive HA filler resulted in significantly better participant-reported outcomes (including quality of life and self-perceived age) compared to either treatment alone.⁴

Longer-Lasting Results

There is experimental evidence that neuromodulation plays a role in optimizing the longevity of injectables.

In a study, sites that received BoNT-A in combination with fillers showed less filler degradation and greater retained volume at 3-month follow-up compared with filler-only controls. 

Botox reduced hyaluronic acid filler degradation by about 42%, and the remaining filler volume was around 50% higher on the side that received Botox.⁵

Reduced Need for High Filler Volumes

Combined botulinum toxin and dermal fillers permit the use of a reduced total filler volume to achieve the same visual correction. 

In practice, chemodenervation decreases repetitive motion and mechanical stress, which otherwise accelerate filler resorption. With reduced degradation, lower volumes of filler can maintain correction for longer.

Treatment Planning and Professional Considerations

The Global Aesthetics Consensus Group lays down several considerations for clinicians before they administer Botox and fillers in conjunction.⁶ They include: 

Assessment Protocol

Effective combination treatment begins long before the syringe is in hand. Every patient needs a structured, anatomically grounded assessment of what their face needs in comparison to what they want. 

Although patients frequently arrive with a specific request (many times, a celebrity photo they hope to emulate), the clinician must reframe the conversation around anatomical diagnosis.

Baseline documentation should include standardized pre-procedure photos. During facial analysis, be aware of the patient’s cultural or ethnic aesthetic preferences.

The intended injection points should be mapped via a dermal pencil to reduce the risk of asymmetry.

Sequencing the Treatments

The sequence is one of the most critical elements in combination therapy. Always start with botulinum toxin using a fine-gauge needle, and tailor the dose to the patient’s muscle mass and degree of hyperdynamic activity. 

Patients with smaller muscle groups, like Asians, need lower doses to reach the desired level of softening. 

Treating the dynamic movement creates a baseline that lets you see exactly which lines represent true static, volume-related changes.

Schedule the next session about two weeks later, once the toxin has reached full effect. Reassess facial movement at this visit; the reduced animation will reveal the remaining volume deficits, contour irregularities, or static folds that require structural support. At this stage, you can introduce hyaluronic acid fillers.

Some practitioners perform all modalities in one sitting, but the Board of Aesthetic Leaders and Investigators advises a staged approach.⁷

When combination therapy is separated into different sessions, you avoid the risk of overcorrection and prevent immediate side effects of bruising and swelling. 

Apply fillers gradually rather than in a single, high-volume session. Try to build support from deeper planes outward over multiple visits so that the face can adapt more naturally. It also gives you better control over the emerging contours in regions prone to swelling. 

Dosage and Product Selection

The Global Aesthetics Consensus Group provides practical guidance for the ideal dosage and product selection for onabotulinumtoxinA and preferred filler categories.⁶ Here are some considerations:

• Glabellar lines are treated with onabotulinumtoxinA dosing from 12 to 40 units; some patients may respond well to as little as 8 units. Superficial Vycross or Hylacross fillers, sometimes diluted, are commonly preferred. 
• Forehead lines need neuromodulator doses from 8 to 25 units adjusted according to muscle strength. Superficial fillers are used for fine lines, while diluted deep volumizers can be used for contouring.
• Lateral periocular lines (crow’s feet) require between 6 and 15 units per side of Botox. Superficial Vycross filler may be added if volume support is needed. 
• Lower eyelid rhytides need minimal neuromodulator dosing, i.e., 0.5–2 units per side, with superficial Vycross filler, placed supraperiosteally or subcutaneously.
• Nasal flare reduction requires 1–4 units, tip elevation 2–6 units, and oblique lines 4–8 units, occasionally up to 10 units of Botox. Deep/midlevel Vycross filler can be used for structural support.
• Botox dosage for cheeks is 1–6 units in small aliquots when intradermal, deep volumizer Vycross is needed for midface projection.
• The masseter muscle requires 15–40 units of Botox, depending on muscle thickness, with deep Vycross fillers.
• Perioral lines can be treated with 1–5 units of neuromodulator and superficial Vycross or Hylacross fillers for fine line support.
• Oral commissure/marionette lines need 2–4 units of Botox per side into the depressor anguli oris with deep volumizer Vycross for the marionette groove.
• Platysmal bands receive 6–12 units of Botox per band, with a maximum total of around 60 units, along with deep volumizer fillers to refine the jawline.

Safety Considerations for Combination Treatment

Dual-modality facial rejuvenation carries an increased risk of adverse events compared with single-modality treatments. 

Adverse events can be categorized broadly into:⁸

• Injection site reactions. These common side effects include prolonged erythema, tenderness, edema, itching, or pain that resolves with supportive measures.
• Hypersensitivity responses. They present as erythema or nonfluctuant nodules accompanied by redness. They are treated with antihistamines or short courses of corticosteroids.
• Infections. They are a serious concern. Signs of infection include warmth, tenderness, edema, or discharge. Prompt intervention with antibiotics, and if needed, debridement and drainage, is necessary.
• Placement errors. Errors in product placement can include nodules or asymmetry that compromise both aesthetic and functional outcomes. Hyaluronidase can be used for the dissolution of fillers if need be.
• Vascular compromise. It is the most urgent complication in combination treatments that presents with blanching, tissue necrosis, or visual disturbances. It needs immediate intervention by surgical specialists. 

Source Botox and Fillers From Maylips

If you are a licensed medical professional seeking high-quality botulinum toxins and dermal fillers for your practice, Maylips offers an ideal solution.

Maylips has been a trusted global supplier of authentic, brand-name medical and aesthetic products since 2014. 

We provide top-tier products at competitive wholesale prices with a price-match guarantee. Let us help you stock your clinic with reliable, professional-grade injectables. You’ll benefit from our industry experience of over 10 years and an extensive network of international partners.

Explore Maylips now. 

FAQs

Do Fillers Last Longer When Used With Botox?

Yes. There is evidence that indicates using Botox alongside hyaluronic acid fillers can extend the duration of filler effects. 

Is It Safe to Inject Botox and Fillers in the Same Session?

Injecting Botox and fillers in the same session can be performed successfully and has been reported in multiple studies with good outcomes. However, the Global Aesthetics Consensus Group generally advises against same-session combinations because of a higher risk of complications. 

Are There Any Complications Unique to Combining Botox and Fillers?

Combining Botox and fillers increases the frequency of common adverse effects and also carries a higher degree of asymmetry. There is also a reported case of a delayed foreign‑body granuloma after sequential Botox and dermal fillers injections.⁹

References

1. Coleman KR, Carruthers J. Combination therapy with BOTOXtm and fillers: the new rejuvnation paradigm. Dermatologic Therapy. 2006;19(3):177-188. doi:https://doi.org/10.1111/j.1529-8019.2006.00072.x
2. Kenner JR. Hyaluronic acid filler and botulinum Neurotoxin delivered simultaneously in the same syringe for effective and convenient combination aesthetic rejuvenation therapy. Journal of drugs in dermatology : JDD. 2010;9(9):1135-1138. https://pubmed.ncbi.nlm.nih.gov/20865847/
3. Molina B, David M, Jain R, et al. Patient Satisfaction and Efficacy of Full-Facial Rejuvenation Using a Combination of Botulinum Toxin Type A and Hyaluronic Acid Filler. Dermatologic Surgery. 2015;41(Supplement 1):S325-S332. doi:https://doi.org/10.1097/dss.0000000000000548
4. CARRUTHERS J, CARRUTHERS A, MONHEIT GD, DAVIS PG. Multicenter, Randomized, Parallel-Group Study of OnabotulinumtoxinA and Hyaluronic Acid Dermal Fillers (24-mg/mL Smooth, Cohesive Gel) Alone and in Combination for Lower Facial Rejuvenation: Satisfaction and Patient-Reported Outcomes. Dermatologic Surgery. 2010;36:2135-2145. doi:https://doi.org/10.1111/j.1524-4725.2010.01797.x
5. İsmail Küçüker, Ibrahim Alper Aksakal, Ahmet Veysel Polat, Murat Sinan Engin, Engin Yosma, Demir A. The Effect of Chemodenervation by Botulinum Neurotoxin on the Degradation of Hyaluronic Acid Fillers. Plastic and reconstructive surgery/PSEF CD journals. 2016;137(1):109-113. doi:https://doi.org/10.1097/prs.0000000000001877
6. Sundaram H, Liew S, Signorini M, et al. Global Aesthetics Consensus. Plastic and Reconstructive Surgery. 2016;137(5):1410-1423. doi:https://doi.org/10.1097/prs.0000000000002119
7. Moon H, Fundaro SP, Goh CL, Hau KC, Paz-Lao P, Salti G. A Review on the Combined Use of Soft Tissue Filler, Suspension Threads, and Botulinum Toxin for Facial Rejuvenation. Journal of Cutaneous and Aesthetic Surgery. 2021;14(2):147-155. doi:https://doi.org/10.4103/JCAS.JCAS_119_20
8. Urdiales-Gálvez F, Delgado NE, Figueiredo V, et al. Treatment of Soft Tissue Filler Complications: Expert Consensus Recommendations. Aesthetic Plastic Surgery. 2018;42(2):498-510. doi:https://doi.org/10.1007/s00266-017-1063-0
9. Lai D, Liu H, Kong L, Cheng S. Delayed complication of botulinum toxin and hyaluronic acid filler injections: A case report. Journal of Cosmetic Dermatology. 2022;21(6):2374-2378. doi:https://doi.org/10.1111/jocd.15016